Literature DB >> 19899267

Natural history, symptoms and treatment of the narcoleptic syndrome.

J D Parkes1, M Baraitser, C D Marsden, P Asselman.   

Abstract

This study describes the clinical features, natural history and treatment of 100 patients with narcolepsy. Over half had one or more affected relatives. Symptoms commenced in adolescence or early adult life in most patients, and remissions were uncommon. Narcolepsy occurred several times each day, often in unusual circumstances and sometimes with little warning. The mean total sleep time of narco-leptics was a little over 9 hours in each 24 hour period, as compared with under 8 in normal subjects. Cataplexy occurred in 93 patients, most commonly when subjects were tired. Attacks were similar in nature to physiological weakness with laughter, although other sudden sensory or emotional stimuli did not cause paralysis of voluntary movement nor loss of muscle tone in normal subjects. Half these patients had frequent dreams before the onset of proper sleep, and 62 had sleep paralysis. This was often frightening, with feelings of suffocation, accompanied by dreams, and of uncertain length. A minority of patients with narcolepsy had muscle aches and jerks before sleep, double vision or loss of focus during cataplexy, went sleep-walking by day, and had daytime hallucinations. Amphetamines had been given to 71 patients for periods of up to 33 years with adequate, but rarely complete, control of narcolepsy. Side effects were common and almost half these patients became tolerant, needing higher dosage to control symptoms. Three patients had a cerebrovascular accident whilst taking amphetamines. Imipramine or clomipramine had ben given in combination with amphetamines to 33 patients for periods of up to 6 years with considerable improvement in both cataplexy and sleep paralysis, and few side effects. Sustained or paroxysmal hypertension as a result of amphetamines or combined treatment did not occur.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 19899267     DOI: 10.1111/j.1600-0404.1975.tb05830.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  7 in total

Review 1.  Addiction and arousal: alternative roles of hypothalamic peptides.

Authors:  Luis de Lecea; Barbara E Jones; Benjamin Boutrel; Stephanie L Borgland; Seiji Nishino; Michael Bubser; Ralph DiLeone
Journal:  J Neurosci       Date:  2006-10-11       Impact factor: 6.167

Review 2.  Neurobiology of consummatory behavior: mechanisms underlying overeating and drug use.

Authors:  Jessica R Barson; Irene Morganstern; Sarah F Leibowitz
Journal:  ILAR J       Date:  2012

3.  Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy.

Authors:  S Nishino; J Arrigoni; J Shelton; T Kanbayashi; W C Dement; E Mignot
Journal:  J Neurosci       Date:  1997-08-15       Impact factor: 6.167

4.  The Epworth Sleepiness Scale: translation and validation study of the Iranian version.

Authors:  Khosro Sadeghniiat Haghighi; Ali Montazeri; Ahmad Khajeh Mehrizi; Omid Aminian; Ania Rahimi Golkhandan; Maryam Saraei; Mojtaba Sedaghat
Journal:  Sleep Breath       Date:  2012-02-11       Impact factor: 2.816

Review 5.  Clinical and neurobiological aspects of narcolepsy.

Authors:  Seiji Nishino
Journal:  Sleep Med       Date:  2007-04-30       Impact factor: 3.492

6.  Narcolepsy: a review.

Authors:  Gbolagade Sunmaila Akintomide; Hugh Rickards
Journal:  Neuropsychiatr Dis Treat       Date:  2011-09-08       Impact factor: 2.570

7.  Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder.

Authors:  Eric Konofal; Wei Zhao; Cédric Laouénan; Michel Lecendreux; Florentia Kaguelidou; Lila Benadjaoud; France Mentré; Evelyne Jacqz-Aigrain
Journal:  Drug Des Devel Ther       Date:  2014-12-01       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.